Referred to the House Committee on Science, Space, and Technology.
The bill would create a National Biopharmaceutical Manufacturing Center of Excellence within the statutory authorities of NIST by competitively awarding a grant or other transaction agreement to a non‑federal eligible entity (a public‑private partnership, institution of higher education, or consortium). The Center’s objectives include advancing scalable and flexible biopharmaceutical manufacturing technologies, improving manufacturing processes and equipment, strengthening supply‑chain resilience, supporting good manufacturing practices and standardization, and running workforce training programs.
Role of federal government: liberals and centrists generally support targeted federal investment; conservatives view it as government overreach and 'picking winners'.
Relative to its intended legislative type, this bill establishes a clear administrative framework to create a National Biopharmaceutical Manufacturing Center of Excellence by amending the NIST Act, authorizing one competitive award to a non‑Federal entity, enumerating objectives and permitted uses of funds, and imposing reporting and IP‑guideline requirements.
The bill would create a National Biopharmaceutical Manufacturing Center of Excellence within the statutory authorities of NIST by competitively awarding a grant or other transaction agreement to a non‑federal eligible entity (a public‑private partnership, institution of higher education, or consortium).
The Center’s objectives include advancing scalable and flexible biopharmaceutical manufacturing technologies, improving manufacturing processes and equipment, strengthening supply‑chain resilience, supporting good manufacturing practices and standardization, and running workforce training programs.
The Director of NIST must solicit applications within 180 days, select one awardee, require periodic public reports (initial, annual progress, and a 5‑year report), and establish intellectual property guidelines in consultation with similar institutions.
On content alone the bill is a targeted, technocratic investment in manufacturing capacity and workforce training with clear objectives and modest near-term authorized funding — features that make it more likely to attract bipartisan backing or to be folded into broader innovation or appropriations packages. Key hurdles are the need for an appropriation, competition with other spending priorities, and Senate procedural realities. The lack of a multi-year authorization or strong mandatory offsets slightly reduces near-term enactment probability.
Relative to its intended legislative type, this bill establishes a clear administrative framework to create a National Biopharmaceutical Manufacturing Center of Excellence by amending the NIST Act, authorizing one competitive award to a non‑Federal entity, enumerating objectives and permitted uses of funds, and imposing reporting and IP‑guideline requirements.
Role of federal government: liberals and centrists generally support targeted federal investment; conservatives view it as government overreach and 'picking winners'.
These are examples from the analysis, not a ranked list of the most-affected groups.
Role of federal government: liberals and centrists generally support targeted federal investment; conservatives view it as government overreach and 'picking winners'.
A mainstream progressive would likely view the bill positively as a targeted federal investment to rebuild domestic biomanufacturing capacity, create skilled jobs, and reduce reliance on foreign supply chains for critical medicines.
They would welcome the workforce training focus and the public reporting requirements, and see potential public‑health benefits from faster domestic scale‑up of biologic medicines.
They would also be attentive to how intellectual property, access to resulting technologies, and environmental and labor standards are handled, and would want assurances that benefits flow equitably to communities and public health needs.
A pragmatic moderate would generally support the bill’s goal of strengthening domestic biomanufacturing capacity, workforce development, and supply‑chain resilience, seeing federal facilitation as appropriate where private investment faces scale‑up barriers.
They would welcome the competitive selection, reporting requirements, and emphasis on co‑investment but want clearer performance metrics, cost controls, and non‑duplication with existing Manufacturing USA institutes or other federal programs.
They would be cautious about the one‑center approach, the sufficiency of $120 million relative to construction and scaling costs, and the clarity of IP rules and public benefit provisions.
A mainstream conservative would be skeptical of a new federally funded center that could pick winners and expand government involvement in industry, preferring market‑driven solutions and state or private sector leadership.
They may acknowledge legitimate concerns about supply‑chain resilience and national security cited in the bill, and see workforce training as useful, but would worry about the federal government using taxpayer dollars to underwrite commercial facilities and potential regulatory or bureaucratic burdens.
Key questions for them would be the extent of ongoing federal subsidies, private cost‑sharing, restrictions on IP, and whether the project crowds out private investment.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone the bill is a targeted, technocratic investment in manufacturing capacity and workforce training with clear objectives and modest near-term authorized funding — features that make it more likely to attract bipartisan backing or to be folded into broader innovation or appropriations packages. Key hurdles are the need for an appropriation, competition with other spending priorities, and Senate procedural realities. The lack of a multi-year authorization or strong mandatory offsets slightly reduces near-term enactment probability.
The bill has not accumulated any surfaced votes yet.
Role of federal government: liberals and centrists generally support targeted federal investment; conservatives view it as government overr…
On content alone the bill is a targeted, technocratic investment in manufacturing capacity and workforce training with clear objectives and…
Relative to its intended legislative type, this bill establishes a clear administrative framework to create a National Biopharmaceutical Manufacturing Center of Excellence by amending the NIST Act, authorizing one compe…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.